International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.
International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.
Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.
Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.
Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.
Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.
Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.
International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.
Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.
Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.
Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.
An International Open Access Journal Devoted to General Medicine.
Gastric cancer remains a major global health burden and a leading cause of cancer-related mortality, with a disproportionate incidence in East Asia and in selected regions of Latin America and Eastern Europe (1,2). Helicobacter pylori (H. pylori) is the predominant infectious cause of noncardia gastric cancer (3–8). The Correa cascade describes progression from chronic active gastritis through atrophy, gastric intestinal metaplasia and dysplasia to invasive adenocarcinoma (6,7,9,10). Although this sequence remains clinically useful, it also exposes an important prevention gap, whereby current guidelines and syntheses of eradication studies distinguish microbiological cure from elimination of residual neoplastic risk (11–14). Longitudinal studies further indicate that atrophy may improve after eradication, whereas intestinal metaplasia often persists or regresses only minimally over time (15,16). Therefore, clearance of the organism may precede, but does not ensure, restoration of a biologically equivalent gastric mucosa.
Eradication remains the cornerstone of gastric cancer prevention. The Maastricht VI/Florence consensus emphasizes that preventive benefit is greatest before advanced atrophy or intestinal metaplasia has developed (11). Management of epithelial precancerous conditions and early neoplasia of the stomach (MAPS III) incorporates high-quality endoscopy, image enhancement, systematic biopsy, Operative Link on Gastritis Assessment (OLGA) and Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) staging and surveillance of advanced precursor lesions (12). The 2025 American Gastroenterological Association Clinical Practice Update likewise recommends individualized screening and surveillance according to H. pylori status, family history, demographic risk, endoscopic findings and histology (17), while International Agency for Research on Cancer guidance extends screen-and-treat strategies to population-level prevention (18). These approaches address the initiating exposure and quantify structural risk, but provide limited insight into whether the mucosal tissue state has recovered biologically.
Randomized trials, cohort studies and systematic reviews consistently show lower rates of incident gastric cancer and metachronous neoplasia after eradication (19–23). Earlier meta-analyses questioned the magnitude of benefit once intestinal metaplasia or dysplasia was present (13,24). Nevertheless, a 2025 synthesis of randomized trials reported risk reduction in these groups, although the effect estimates varied by region, duration of follow-up and study quality (14). Therefore, the remaining question is not whether eradication is beneficial, but whether residual risk is fully explained by persistent structural damage or whether additional tissue-level features convey independent information.
Against this background, the present review examined whether post-eradication mucosal immune trajectories add information beyond established measures of structural risk. Specifically, it distinguished candidate immune signals from residual inflammation, metaplastic architecture, epithelial-field alterations and exposure misclassification; separated biological persistence from clinical utility; and defined the longitudinal comparisons needed to support or refute the hypothesis.
The starting premise is that H. pylori eradication reduces the risk of primary and metachronous gastric neoplasia (19–23), although effect estimates in established intestinal metaplasia or dysplasia differ across syntheses (13,14,24) and metaplastic tissue may persist (15,16). The working hypothesis is that a subset of eradicated patients may retain localized immune abnormalities that are not explained by active inflammation, morphologic burden or epithelial-field alterations. Such a signal would need to recur in anatomically matched samples, show functional relevance and retain information after competing tissue variables have been considered. Otherwise, it is more appropriately interpreted as residual infection-associated remodeling rather than a distinct clinically informative state.
The present concept-driven narrative review evaluated a falsifiable translational proposition rather than estimating a pooled effect. Searches were updated through 1 July 2026 in PubMed/MEDLINE (https://pubmed.ncbi.nlm.nih.gov/) and supplemented by Web of Science Core Collection (https://pubmed.ncbi.nlm.nih.gov/) searches and forward and backward citation tracking. Search blocks covered H. pylori exposure and eradication; gastric atrophy, intestinal metaplasia, dysplasia and metachronous neoplasia; local immune responses, including tissue-resident memory T-cell (TRM) biology; single-cell and spatial methods; post-eradication tissue trajectories; and recent reviews of residual risk, oncogenic signaling and gastric immune tolerance. Study selection prioritized relevance to human gastric mucosa, longitudinal or paired designs, directness to the proposition under evaluation and explicit measurement of competing structural or epithelial fields. Animal models, organoids, established gastric cancer and other tumor types were included only as indirect mechanistic or methodological precedents.
No restriction was placed on the start date, and only English-language reports were considered. Foundational studies were retained when they established staging systems, pathogenetic concepts or metaplastic biology. As the present review was concept driven, no pooled effect estimate was calculated, and no formal risk-of-bias instrument was applied. Instead, each major inference was classified by disease stage, study design, population relevance, directness of evidence and the specific proposition it could support. Evidence was downgraded when it relied on cross-sectional sampling, post-resection populations, unvalidated proxies or mechanistic analogy. Table SI reports the search framework and selection principles, and Table SII provides a study-level appraisal of the directness and limitations of the evidence.
The evidence base falls into the following four categories: i) Trials, cohorts and systematic reviews establish the residual-risk premise, with eradication reducing, but not eliminating, gastric cancer risk; ii) human tissue studies in gastritis, atrophy, intestinal metaplasia or dysplasia characterize remodeling associated with infection and precursor lesions; iii) paired post-eradication studies provide the most direct evidence of reversibility or persistence; and iv) findings from animals, organoids, established gastric cancer and other tumor types remain mechanistic analogies rather than evidence in gastric precursor tissue.
Evidence was weighted according to its directness to the claim rather than the sophistication of the technology used. Paired functional measurements in human tissue after confirmed eradication provide the strongest evidence for the central hypothesis. Molecular, histologic, microbiome and spatial measurements can reveal discordant recovery but remain contextual evidence or candidate proxies until linked to functional immune activity. Cross-sectional human atlases define states associated with infection or precursor lesions, whereas model systems and studies of established cancers identify mechanisms for subsequent testing. Confirmation would require verified exposure status, paired measurements of immune persistence and function, concurrent assessment of morphology and the epithelial field, and prospective dysplasia or gastric cancer outcomes in the same participants. Among the studies identified through the present search, none incorporated this complete evidentiary chain. Therefore, the available evidence supports infection-associated remodeling and heterogeneous recovery, while a durable, clinically meaningful immune state remains unproven, as summarized in Table I.
Current risk stratification for gastric precursor lesions relies on endoscopic and histologic assessment. OLGA relates the extent and severity of atrophy to gastric cancer risk (25), whereas OLGIM uses intestinal metaplasia as a more reproducible surrogate (26). The updated Sydney System standardizes the grading of inflammation, activity, atrophy, intestinal metaplasia and H. pylori status (27). MAPS II and III translate these measures into surveillance recommendations (12,28), and the Kyoto consensus classifies H. pylori gastritis as both an infectious disease and a precursor condition (29). Prospective surveillance data and endoscopic grading systems further support risk stratification of gastric precursor lesions (30,31), and their continued clinical use reflects their standardization, feasibility and established relevance.
The principal limitation of OLGA, OLGIM and Endoscopic Grading of Gastric Intestinal Metaplasia (EGGIM) is one of scope, not validity. These systems quantify the extent and distribution of atrophy or intestinal metaplasia, yet patients within the same morphologic category may differ in host susceptibility and dietary exposure (32–34). Infection history and gastric microbial ecology introduce further heterogeneity (8,29,35–39). The relevant issue is whether tissue-level functional measures add risk information after established clinical and structural variables have been accounted for.
H. pylori-driven carcinogenesis extends beyond direct epithelial injury. Adhesion, cytotoxin-associated gene A protein (CagA), vacuolating cytotoxin A (VacA), the cag type IV secretion system, urease activity, inflammatory signaling and disruption of epithelial polarity or β-catenin regulation all contribute to disease progression (6,7,40–46). Experimental and translational studies implicate gastric stem-cell and regenerative programs in injury-associated epithelial remodeling and carcinogenesis (10,47–49), while immune and inflammatory responses further shape the mucosal environment during persistent infection (6,7,50,51). Prospective human evidence also links H. pylori infection to the subsequent development of gastric cancer (52). Therefore, a precursor lesion is best viewed as a dynamically organized tissue system, although epithelial clones and metaplastic architecture may still account for a substantial proportion of residual risk.
Post-eradication immune-associated remodeling is used in the present review as a provisional term for anatomically localized immune features detected after confirmed H. pylori eradication (53–55). It does not denote a disease entity, a clinical label or evidence of a causal contribution to residual risk. The epithelial field refers to metaplastic, clonal and epigenetic alterations distributed within mucosa at risk (56–58). For operational purposes, epithelial-field burden should be separated into structural and molecular components. The structural field should be represented, at minimum, by OLGIM stage, the anatomical extent and distribution of intestinal metaplasia assessed by EGGIM or systematically mapped histology, and metaplasia subtype, including the extent or proportion of incomplete-type metaplasia where available (12,26,27,31,57). The molecular epithelial field comprises quantitatively assessed clonal/mutational and/or methylation burden in non-neoplastic mucosa (56,57). As no fixed methylation-marker panel has been validated specifically for post-eradication precursor mucosa (56,57), marker selection should be prespecified and analytically validated rather than defined by an arbitrary numerical minimum (59,60). To qualify as a distinct immune-associated signal, a feature must be linked to previous exposure, localized to precursor-lesion mucosa or its surrounding field, reproducible after active inflammation and reinfection have been excluded, functionally relevant, and not explained by morphologic or epithelial-field burden.
Cell abundance alone cannot establish persistence (55,61,62). More compelling evidence would require recurrence in anatomically matched paired tissue together with measurable functional immune activity, such as altered antigen presentation, myeloid function, T-cell persistence or ex vivo effector capacity (53,61,63,64). Pathway-level and spatial measurements should remain candidate proxies until validated against function (55,60,62).
Epithelial, stromal and microbial measurements provide essential context and competing explanations, but do not in themselves establish immune persistence (35,55–57). The greater the structural burden, the more important it becomes to show that an immune measurement contributes independent information (12,30,59,65).
Clinical relevance requires more than biological persistence. A tissue feature must remain associated with prespecified dysplasia or gastric cancer outcomes after clinical, morphologic, infectious and epithelial-field variables have been considered (12,54,56,57,59,60,65). The association should be replicated in external cohorts, and any improvement in risk stratification or surveillance decisions should provide sufficient clinical benefit to justify additional biopsies, assay costs and the potential harms of misclassification (17,65,66).
Causality and prediction should be evaluated separately. A persistent signal may be biologically genuine yet add little to clinical risk assessment, whereas a useful predictor does not need to be causal. Therefore, Table II distinguishes discovery-stage tissue features from clinically useful markers, which require a parsimonious assay, external validation and demonstrable clinical utility (59,60,65,66).
Trained immunity, tissue-resident memory and field cancerization describe different forms of biological persistence. Trained immunity refers to durable functional reprogramming of innate cells or their progenitors (67), TRM to antigen-experienced lymphocytes retained within tissue (68), and field cancerization to spatially distributed molecular alterations in epithelium at risk (58). Each provides a plausible precedent for incomplete biological normalization after H. pylori eradication, but none is equivalent to the immune-associated state considered in the present review.
A clinically relevant post-eradication immune signal would need to persist after confirmed eradication, demonstrate functional relevance, and retain outcome information after metaplastic, clonal and methylation fields have been considered. Tissue residence or mechanistic similarity alone is insufficient; these concepts are useful only insofar as they define testable comparisons involving exposure dependence, localization, persistence, function and residual outcome information.
Recent high-resolution studies have documented infection-associated differences in the human gastric immune ecosystem. A 2025 study combining single-cell RNA sequencing with T-cell receptor analysis compared H. pylori-positive and H. pylori-negative gastric samples and identified reduced antigen presentation and phagocytic programs, altered monocyte-to-macrophage differentiation and attenuated T-cell states in infected tissue (61). A separate multi-omic survey of asymptomatic infection reported coordinated microbial and immune differences (69). These cross-sectional studies establish measurable remodeling during active infection, but neither included paired gastric mucosal biopsies obtained from the same individuals before and after H. pylori eradication.
Single-cell and spatial studies have resolved epithelial lineages, tissue organization and localized cell-cell interactions in gastritis and intestinal metaplasia (62,70–75). Genomic and methylation studies have also identified clonal and epigenetic heterogeneity within intestinal metaplasia (56,57). These datasets generate candidate epithelial-immune relationships, but cannot determine whether an immune-associated feature persists after eradication.
More direct post-eradication tissue evidence has also emerged. A 2026 single-cell study of 22 human gastric antral mucosal samples spanning active infection and post-eradication chronic atrophic gastritis identified persistent immunomodulatory fibroblast states and an immunosuppressive stromal-epithelial niche after eradication (55). This study moves beyond tumor-stage analogy by examining post-eradication precursor mucosa directly. However, its stage-stratified design did not provide anatomically paired longitudinal sampling, direct immune-function assays or prospective neoplastic outcomes.
Post-eradication studies indicate heterogeneous recovery across immune, molecular, structural, microbial, stromal and outcome-linked domains (15,16,35,36,53–55,76). Ihan et al (53) directly measured selected T-cell responses after eradication, whereas Kim et al (54) provided the closest currently available outcome-linked immune evidence through post-resection CD8-associated trajectories. The remaining studies primarily assessed gene expression, histology or microbial composition (15,16,35,36,76). Differences in population, sampling and outcome definition preclude an integrated causal inference. The beginning of section 7 and Table SII provide the study-level appraisal, and Fig. 1 summarizes the competing trajectories.
Monocytes, macrophages, dendritic cells and neutrophils participate early in the gastric response to H. pylori (50). Single-cell data from infected human tissue show altered monocyte-to-macrophage differentiation and reduced phagocytic or antigen-presentation programs, while atlases of precursor lesions and established cancer reveal myeloid states that extend beyond conventional binary M1/M2 labels (61,72,77–79). These observations establish heterogeneity during infection or in tumors, not persistence after eradication.
Studies of established gastric cancer have described secreted phosphoprotein 1 (SPP1)-positive macrophage-stromal interactions associated with matrix remodeling and immune suppression (80–82). Within the present framework, these findings identify spatial relationships for testing in paired precursor tissue and do not define a precursor phenotype.
Therefore, post-eradication studies should prioritize anatomically matched measures of antigen-presentation capacity, phagocytic function and myeloid-T-cell or myeloid-stromal interactions rather than macrophage abundance or binary polarization labels. A credible precursor-lesion signal requires concordant functional evidence, or a proxy that has been validated against such evidence. Within the tissue-based framework, a post-eradication myeloid signal would be informative only if it persists in anatomically matched mucosa, retains functional abnormality and contributes information beyond structural and infectious explanations.
Effective immune surveillance depends on a sequence of antigen capture, presentation, T-cell priming, clonal expansion and effector activity. Infection-stage data indicate that impaired antigen-presentation programs can coexist with altered T-cell states (61), but no study of precursor tissue has followed this coupled disturbance longitudinally after eradication.
H. pylori-specific immunity includes protective, tolerogenic and tissue-damaging components. Human studies have identified H. pylori-specific regulatory T-cell and T helper 1 responses (83,84). Experimental models suggest that regulatory T cells, dendritic-cell-mediated regulatory T-cell skewing, γ-glutamyl transpeptidase/VacA-dependent tolerance and inflammasome-related signaling influence microbial persistence and tissue injury (85–88), while the interleukin (IL)-23/IL-17 axis provides an additional inflammatory pathway (89). The relevant question is not whether these programs operate during infection, but whether their balance is restored once the organism has been cleared.
TRMs provide a more specific candidate cellular substrate for localized immune persistence. Gastric H. pylori-specific CD8+ TRM populations have been characterized in humans and experimental models, including CagA-specific cells with antigen-specific effector activity (63). A 2025 human study further reported increased gastric mucosal CD8+ TRMs in H. pylori-infected subjects, recruitment through the C-X-C motif chemokine receptor 5/C-X-C motif chemokine ligand 13 axis and enhanced interferon-γ (IFN-γ) and tumor necrosis factor-α production (90). Experimental studies have demonstrated that CagA-specific gastric CD8+ TRMs contribute to controlling H. pylori during early infection (63), while a subsequent eradication and reinfection study showed that CagA-dependent Hobit+ gastric TRMs can persist long term and confer protection against reinfection (91). These findings establish biological plausibility for a durable resident T-cell compartment, but they do not demonstrate that functionally abnormal TRM populations persist after eradication in high-risk human precursor lesions or independently contribute to subsequent neoplasia.
Notably, an ex vivo single-cell analysis of a gastric intestinal metaplasia biopsy from one patient identified a resident-memory CD8+ T-cell cluster, providing direct precursor-stage evidence for the presence of a TRM compartment (64). However, this single-biopsy tissue-engineering study was designed to evaluate ex vivo cellular responses rather than longitudinal persistence after H. pylori eradication.
Therefore, within the present framework, TRM should be treated as a candidate substrate for persistence rather than evidence that persistence has occurred. Their relevance would require longitudinally matched assessment of residency-associated phenotype, antigen specificity or function after confirmed eradication, together with concurrent measurement of structural and epithelial-field burden. More broadly, T-cell phenotype or abundance becomes clinically informative only when persistent residency-associated or functional abnormalities are demonstrated after eradication and remain distinct from competing tissue-field explanations.
Clinical records commonly reduce H. pylori status to positive, negative or eradicated. This simplification obscures distinctions among active infection, remote infection, time since eradication and reinfection, while antibiotic exposure, acid suppression and the diagnostic method can influence infection ascertainment or microbial measurements (11,17,29,35,36). Longitudinal human studies also suggest that microbial recovery is not uniform. In a randomized paired-biopsy study, eradication increased microbial diversity, but specific microbial patterns were associated with persistent inflammation, atrophy or intestinal metaplasia at one year (35). A 2026 longitudinal study of patients treated endoscopically for gastric cancer likewise identified substantial shifts in community structure after eradication (36). These findings position the microbiome as a contextual modifier and a competing explanation; neither demonstrates a persistent immune mechanism in precursor tissue from individuals without previous gastric neoplasia.
Therefore, exposure history should be reconstructed explicitly rather than represented by a binary category. Microbiome data should remain candidate modifiers until they show reproducible value independent of medication, diet, geography, infection status and morphologic disease (8,34–39). Therefore, within the tissue-based framework, infection history and microbiome composition should be treated as mandatory competing variables and contextual modifiers rather than as evidence of persistent immune dysfunction themselves.
Gastric intestinal metaplasia is a plausible substrate for persistent tissue change as regenerative reprogramming, gland reconstruction, immune infiltration, stromal alteration and spatial heterogeneity coexist within the lesion (56,57,62,70–75). Spasmolytic polypeptide-expressing metaplasia models support continuity between injury and altered tissue architecture, but do not demonstrate immune persistence after eradication (92–96).
Genomic, single-cell and methylation studies show that intestinal metaplasia contains distinct epithelial trajectories, clonal structures and subtype-specific methylation programs (56,57,74,75). Therefore, any immune association must be evaluated after adjustment for the extent and subtype of metaplasia, dysplasia, OLGIM stage and epithelial-field burden.
The practical question is whether immune or stromal measurements retain risk information after these established structural variables have been considered. Until this has been demonstrated, a high-risk immune label would be premature.
Across cancer biology, inflammation can remodel tissue through cytokine signaling, extracellular-matrix turnover, angiogenesis and regenerative programs (97,98). However, in gastric precursor mucosa, a putatively persistent immune mechanism must be demonstrated within the tissue architecture rather than inferred from transient inflammatory-cell counts.
Fibroblasts may link altered glands to immune-cell behavior. Direct post-eradication human evidence is available from a 2026 single-cell study of 22 human gastric antral mucosal samples spanning different stages of H. pylori infection and post-eradication chronic atrophic gastritis (55). The study identified two subpopulations of immunomodulatory cancer-associated fibroblasts (iCAFs): Cellular communication network factor 2-expressing iCAF1 and Complement component 3-expressing iCAF3. These labels represent transcriptomically defined fibroblast subpopulations characterized by their respective marker-expression profiles. Both subpopulations remained detectable after eradication, particularly in patients without pathological improvement, and were associated with an immunosuppressive stromal-epithelial niche (55). This study strengthens the case for stromal persistence in precursor mucosa, but its stage-stratified design lacked anatomically matched paired sampling and prospective neoplastic outcomes. Tumor-stage SPP1-positive macrophage-fibroblast networks remain mechanistic analogies rather than precursor-stage proof (80–82).
Taken together, direct post-eradication human observations and tumor-stage studies identify plausible stromal-immune relationships, but only the former sample precursor mucosa after eradication. Establishing a persistent immune mechanism still requires anatomically standardized paired human tissue with functional validation. Therefore, Fig. 2 distinguishes observed post-eradication stromal remodeling from candidate immune-persistence relationships that still require longitudinal validation.
The most direct longitudinal evidence of immune-function change after eradication comes from Ihan et al (53). In 24 patients with duodenal ulcer, gastric mucosal T-cell CD25 expression and IFN-γ production declined at 3 and 12 months after H. pylori eradication (53). These findings demonstrate reversibility of selected infection-dependent T-cell responses. However, the study population did not have gastric precursor disease, and the immune environment of duodenal ulcers may differ substantially from that of extensive atrophy or intestinal metaplasia. Therefore, the observed reversibility cannot be assumed to generalize to high-risk precursor mucosa. The decline in CD25 expression and IFN-γ production could theoretically reflect contraction or phenotypic remodeling of a tissue-resident T-cell compartment after removal of bacterial antigen, but the study did not phenotype residency-associated markers or distinguish resident from recirculating T cells. Therefore, TRM clearance cannot be inferred from these data. Only a restricted set of T-cell functions was examined, and neither epithelial-field burden nor subsequent neoplastic outcomes were assessed.
Paired molecular and structural studies show discordant tissue recovery, but do not directly establish persistent immune function. A randomized, placebo-controlled study examined 54 gastric biopsies from 27 participants and identified changes in gene expression one year after eradication, demonstrating molecular responsiveness in gastric precursor disease (76). Among 65 patients with intestinal metaplasia, 44 (67.7%) retained metaplasia after a mean follow-up of 33.9 months, and persistence was associated with greater baseline nuclear β-catenin expression (15). In a prospective cohort of 172 patients followed histologically for up to 17 years, atrophy improved after eradication, whereas intestinal metaplasia did not change significantly at either biopsy site (16). Therefore, molecular or inflammatory improvement may coexist with structural persistence, a pattern that primarily supports epithelial and tissue-field explanations.
Among the available studies, Kim et al (54) provide the closest currently available human evidence linking post-eradication immune remodeling to a clinical neoplastic outcome. In 36 patients who developed metachronous gastric neoplasia after eradication and 36 matched controls, post-eradication histologic and CD8-associated trajectories differed between outcome groups (54). This head-to-head comparison gives the study greater evidentiary weight than a purely cross-sectional immune association. Nevertheless, the measurements were immunohistochemical proxies rather than direct functional assays, and all participants had previously undergone endoscopic resection for gastric neoplasia, implying a pre-existing neoplastic epithelial and stromal field. Therefore, the study supports an outcome-associated immune trajectory but does not establish persistent immune dysfunction as an independent risk mechanism in a primary-prevention population. Separately, a 2026 single-cell study of 22 human antral mucosal samples spanning infected and post-eradication chronic atrophic gastritis identified persistent immunomodulatory fibroblast states and an immunosuppressive stromal-epithelial niche after eradication (55). This provides direct post-eradication human tissue evidence of microenvironmental persistence, but not paired longitudinal immune-function evidence or prospective neoplastic outcome association. Microbial studies provide additional context, including a randomized cohort showing marked microbial remodeling at one year after eradication, with specific taxa associated with persistent inflammation, atrophy or intestinal metaplasia (35), and a 2026 post-resection cohort which showed non-uniform microbiome changes after eradication (36). These observations are contextual rather than functional immune evidence.
The evidence hierarchy is complementary rather than uniform. Ihan et al (53) provide the most direct longitudinal evidence of selected immune-function reversibility, whereas Kim et al (54) provide the strongest currently available outcome-linked immune evidence. Neither study establishes a persistent, functionally defined immune state that independently predicts incident neoplasia in an eradicated primary-prevention population. Molecular, structural, microbial and stromal single-cell observations support heterogeneous recovery but arise from non-equivalent populations and biological domains. The 2026 post-eradication single-cell study increases the directness of tissue-persistence evidence, as it samples chronic atrophic gastritis after eradication, but does not complete the within-person functional-outcome chain (55). Among eligible studies identified through the present search, none assessed immune persistence and function, epithelial-field burden and prospective incident outcomes in the same eradicated individuals without previous gastric neoplasia. Therefore, current human evidence supports heterogeneous recovery, but not an independent persistent immune state.
A total of four longitudinal patterns are analytically useful. A normalizing trajectory denotes resolution of active inflammation and infection-dependent immune activation (53,76). Structural persistence refers to retained atrophy or intestinal metaplasia (15,16); epithelial clonal and methylation fields should be treated as competing tissue-field explanations rather than assumed post-eradication trajectories (56,57). A persistently altered trajectory requires reproducible functional abnormalities, pathway-level changes or biologically validated spatial features after morphology and inflammation have been considered (53–55,61,62). Reinfection, inconsistent biopsy location, medication exposure, inadequate tissue or assay instability define an indeterminate trajectory (11,17,27,35,59,60,65). These are research constructs, not clinical labels.
The most informative confirmation cohort would include individuals with verified eradication, no previous gastric neoplasia and a guideline-defined high-risk precursor phenotype, such as OLGIM III–IV or extensive endoscopic intestinal metaplasia (12,17,28,30,31). The key comparison is not simply between infected and eradicated tissue, but between eradicated patients with and without reproducible immune abnormalities after concurrent assessment of morphology, epithelial-field burden, reinfection, medication exposure and sampling location. Post-resection cohorts remain valuable for secondary validation, but cannot replace primary-prevention evidence, as previous neoplasia implies a different epithelial and stromal field.
The hypothesis should be tested against explicit failure criteria. A candidate feature must recur in standardized paired biopsies after active inflammation, reinfection, medication effects and sampling variation have been addressed (11,17,27,35), and it must not simply track OLGIM stage, metaplasia extent, epithelial clone burden, biopsy site or baseline inflammation (12,26,27,56,57). A pathway-level or spatial proxy requires validation against functional immune activity and stage-appropriate outcomes (53–55,59,60,62,65). Resolution after eradication (53,76), inconsistent replication or absence of information beyond morphologic and epithelial-field measures (12,56,57,59,65) would favor the more limited interpretation of infection-associated remodeling.
Taken together, the evidence supports a staged rather than a unitary interpretation. Eradication reduces primary and metachronous gastric neoplasia (19–23) and reverses selected infection-dependent T-cell responses (53), whereas structural and microbial abnormalities may persist (15,16,35,36). Clonal and epigenetic studies reveal additional heterogeneity within the epithelial field, but its trajectory after eradication remains unresolved (56,57). Among the studies identified through the present search, none provided longitudinal primary-prevention evidence that a persistent immune feature predicted incident neoplasia independently of structural and epithelial-field burden. Therefore, the remaining issues are the adequacy of competing explanations, the evidence needed for confirmation and the limits of clinical translation.
The present review organized the available evidence according to disease stage, directness and competing explanations rather than proposing a new disease label. Distinguishing remodeling during infection from persistence after eradication, and biological function from clinical utility, clarifies what is required before an immune-associated signal can be interpreted independently of structural disease, epithelial-field alterations or exposure misclassification.
Residual risk may arise through several non-exclusive mechanisms. Metaplastic architecture may remain abnormal as gland identity and tissue organization reverse slowly, if at all. Clonal and methylation fields within intestinal metaplasia may account for outcome variation independently of immune measurements, although their persistence after eradication has not been established (56,57). Host susceptibility and dietary exposure may modify baseline risk (32–34), while infection status and gastric microbial ecology may vary with eradication and geography (8,29,35–39). Therefore, medication exposure, biopsy location and sampling quality should be recorded as design variables. A persistent immune signal may be biologically genuine yet remain secondary to a more influential structural or epithelial process.
The critical analytical test is whether mucosal immune measurements explain outcome variation after structural, epithelial, infectious and exposure-related alternatives have been incorporated adequately. Adding an immune panel to an incomplete baseline model would exaggerate its contribution. Therefore, Table III treats competing explanations as obligatory comparators rather than peripheral caveats.
A clinically credible baseline model should cover four domains. Exposure assessment should reconstruct current or previous H. pylori infection, timing of eradication, reinfection, antibiotic use, acid suppression, diet and relevant host susceptibility (11,17,29,32–36). Morphologic assessment should include high-quality endoscopy, Sydney-system pathology, OLGA/OLGIM stage, EGGIM where high-quality endoscopic mapping is available, the extent and anatomical distribution of metaplasia, metaplasia subtype and dysplasia (12,25–31). Therefore, a minimum structural epithelial-field core should include OLGIM stage, metaplasia extent/distribution and subtype. In molecularly profiled cohorts, at least one prespecified quantitative epithelial-field measure, such as methylation burden or clonal/mutational burden, should additionally be evaluated where tissue availability permits (56,57). Only then should a small prespecified set of immune-function measurements or functionally validated proxies be tested for added value.
Analysis should begin with the clinical, morphologic, exposure and epithelial-field model. Candidate immune markers can then be added to assess independent and incremental risk information. Prespecification, transparent reporting, calibration, external validation, risk-of-bias assessment and clinical utility should follow established principles for biomarkers and prediction models (59,60,65,66). Molecular subtypes defined in established gastric cancer (99,100) may suggest biological continuity but cannot substitute for measurements in precursor-lesion mucosa. Likewise, digital pathology is a measurement platform, not evidence that the proposed biological state exists.
Confirmation requires a longitudinal cohort of individuals without previous gastric neoplasia. Each participant should undergo verified assessment of eradication or reinfection, anatomically standardized paired sampling, and direct measurement of immune function or a functionally validated proxy. Morphology, epithelial-field burden and prospective dysplasia or gastric cancer outcomes should be assessed concurrently. Cross-study triangulation can justify further investigation but cannot replace this within-cohort chain. Sampling intervals, assays, candidate measurements and analytical plans should be prespecified and reported transparently (59,60,65). The corresponding measurement domains, limitations of the available direct evidence and key longitudinal tests are summarized in Table SIII. High-dimensional atlases and post-resection associations can identify candidate signals but cannot establish persistence or clinical relevance on their own.
Incident dysplasia or gastric cancer in individuals without previous gastric neoplasia should serve as the primary clinical endpoints, with metachronous neoplasia after endoscopic resection used for secondary validation. Biological persistence requires exposure linkage, localization and demonstrable function. Clinical utility additionally requires technical stability, external validation, calibration, incremental value and a measurable improvement in surveillance decisions (59,60,65,66). The longitudinal validation sequence integrating these requirements is summarized in Fig. 3.
At present, no tissue-based test derived from this framework is ready for routine use. Surveillance should continue to follow established recommendations and high-quality endoscopic and histologic assessment, and gastric dysplasia should be managed according to existing standards (12,17,28,101,102). The immediate translational value lies in defining research-eligible populations rather than changing care. Patients with confirmed eradication and OLGIM III–IV or extensive intestinal metaplasia should continue to be managed under current guidance, while candidate immune or spatial assays should be confined to prospective studies of individuals without previous gastric neoplasia and evaluated against incident dysplasia or cancer (12,17,28,30,31).
Any viable assay must be parsimonious, reproducible across biopsy sites and compatible with routine pathology. Adoption would require sufficient clinical benefit to offset additional biopsies, cost, false reassurance and unnecessary endoscopy. Digital pathology may facilitate measurement, but its availability does not establish the existence of the proposed state or the clinical validity of a risk classifier.
Recent reviews and perspectives have primarily addressed residual-risk management after eradication, infection-phase oncogenic signaling or immune tolerance in established gastric cancer (103–105). The present review instead focuses on precursor-lesion mucosa after eradication in individuals without previous gastric neoplasia and asks whether paired immune measurements add information beyond structural and epithelial-field burden. This emphasis shifts the discussion from pathway cataloguing to directness of evidence, competing explanations, falsifiability and clinical increment.
The present review had several limitations. First, the integrated human evidence chain remains incomplete. Among eligible studies identified through the present search, none measured confirmed exposure, paired immune persistence and function, epithelial-field burden, incident cancer outcomes and incremental clinical value within the same prevention cohort. Available studies triangulate across non-equivalent populations and biological domains, and only selected T-cell measurements assess immune function directly. The incorporated TRM studies establish infection-stage biology, experimental durability or precursor-stage presence, but do not provide longitudinal evidence of abnormal TRM persistence after eradication in high-risk human precursor cohorts (63,64,90,91). The 2026 post-eradication single-cell study strengthens direct evidence of persistent stromal/immune-associated remodeling, but its stage-stratified design does not establish within-person persistence or clinical outcome independence (55). Second, the concept-driven narrative design, restriction to English-language reports and reliance on published studies may introduce selection, availability and interpretive bias. Third, several proposed myeloid-stromal and spatial mechanisms still derive from established gastric cancer, animal models, organoids or other tumor types and cannot be assumed to operate in precursor mucosa after eradication (47,48,77,80–82,92–96,106).
The strongest outcome-linked immune observations were obtained in patients with previous gastric neoplasia (54), limiting generalizability to primary-prevention populations. Previous neoplasia also implies a different epithelial and stromal field, making these cohorts unsuitable as the sole basis for a marker intended for primary prevention. Even a reproducible mucosal immune state may prove clinically unusable because of sampling variation, platform dependence, cost, overfitting or a lack of incremental value.
The highest-priority next step is multicenter validation using paired biopsies from individuals without previous gastric neoplasia (12,17,53–55). Repeated assessment of eradication status and immune function should be interpreted alongside morphology, epithelial clonal or methylation burden and prospective outcomes in the same participants (11,12,53,55–57). The decisive question is whether a parsimonious immune assay improves risk stratification or surveillance decisions beyond a complete clinical, morphologic, exposure and epithelial-field baseline (12,17,59,60,65,66).
H. pylori eradication reduces gastric cancer risk but does not restore all high-risk gastric mucosa to a uniform biological state. Current human evidence supports heterogeneous post-eradication recovery, but does not yet establish a persistent, functionally defined immune state that predicts incident neoplasia independently of structural and epithelial-field burden. Therefore, the principal contribution of the present review is a falsifiable framework that separates immune persistence from residual inflammation, tissue-field damage and clinical utility. The immediate research priority is a prospective paired-biopsy cohort in individuals without previous gastric neoplasia that integrates verified eradication, immune function, epithelial-field measurements and incident outcomes. Until such evidence is available, candidate immune markers should remain investigational, and surveillance should continue to follow established endoscopic and histologic criteria.
Not applicable.
This review was supported by the Yunnan Provincial Department of Science and Technology Kunming Medical University Special Projects (grant no. 202401AY070001-197).
Not applicable.
JC and BT contributed to study conception, literature review, manuscript drafting and table organization. LZ and JC supervised the study design, revised key academic content and approved the final manuscript. All authors contributed to writing and revising the manuscript. All authors read and approved the final version of the manuscript. Data authentication is not applicable.
Not applicable.
Not applicable.
The authors declare that they have no competing interests.
|
EGGIM |
Endoscopic Grading of Gastric Intestinal Metaplasia |
|
OLGA |
Operative Link on Gastritis Assessment |
|
OLGIM |
Operative Link on Gastric Intestinal Metaplasia Assessment |
|
TRM |
tissue-resident memory T cell |
|
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024.PubMed/NCBI | |
|
Smyth EC, Nilsson M, Grabsch HI, van Grieken NCT and Lordick F: Gastric cancer. Lancet. 396:635–648. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
de Martel C, Georges D, Bray F, Ferlay J and Clifford GM: Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis. Lancet Glob Health. 8:e180–e190. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Plummer M, Franceschi S, Vignat J, Forman D and de Martel C: Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer. 136:487–490. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wroblewski LE, Peek RM Jr and Wilson KT: Helicobacter pylori and gastric cancer: Factors that modulate disease risk. Clin Microbiol Rev. 23:713–739. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Amieva M and Peek RM Jr: Pathobiology of Helicobacter pylori-induced gastric cancer. Gastroenterology. 150:64–78. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Polk DB and Peek RM Jr: Helicobacter pylori: Gastric cancer and beyond. Nat Rev Cancer. 10:403–414. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Wizenty J and Sigal M: Helicobacter pylori, microbiota and gastric cancer-principles of microorganism-driven carcinogenesis. Nat Rev Gastroenterol Hepatol. 22:296–313. 2025. View Article : Google Scholar : PubMed/NCBI | |
|
Correa P: Human gastric carcinogenesis: A multistep and multifactorial process-first American cancer society award lecture on cancer epidemiology and prevention. Cancer Res. 52:6735–6740. 1992.PubMed/NCBI | |
|
Liabeuf D, Oshima M, Stange DE and Sigal M: Stem cells, Helicobacter pylori, and mutational landscape: Utility of preclinical models to understand carcinogenesis and to direct management of gastric cancer. Gastroenterology. 162:1067–1087. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C, Gasbarrini A, Hunt RH, Leja M, O'Morain C, et al: Management of Helicobacter pylori infection: The Maastricht VI/Florence consensus report. Gut. 71:1724–1762. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Dinis-Ribeiro M, Libânio D, Uchima H, Spaander MCW, Bornschein J, Matysiak-Budnik T, Tziatzios G, Santos-Antunes J, Areia M, Chapelle N, et al: Management of epithelial precancerous conditions and early neoplasia of the stomach (MAPS III): European society of gastrointestinal endoscopy (ESGE), European Helicobacter and microbiota study group (EHMSG) and European society of pathology (ESP) guideline update 2025. Endoscopy. 57:504–554. 2025. View Article : Google Scholar : PubMed/NCBI | |
|
Chen HN, Wang Z, Li X and Zhou ZG: Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: Evidence from a meta-analysis. Gastric Cancer. 19:166–175. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Fu Q, Yu H, Liu M, Chen L, Chen W, Wang Z and Li W: Effect of Helicobacter pylori eradication on gastric cancer risk in patients with intestinal metaplasia or dysplasia: A meta-analysis of randomized controlled trials. Front Microbiol. 16:15305492025. View Article : Google Scholar : PubMed/NCBI | |
|
Hung KH, Wu JJ, Yang HB, Su LJ and Sheu BS: Host Wnt/beta-catenin pathway triggered by Helicobacter pylori correlates with regression of gastric intestinal metaplasia after H. pylori eradication. J Med Microbiol. 58:567–576. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Kodama M, Okimoto T, Mizukami K, Hirashita Y, Wada Y, Fukuda M, Matsunari O, Okamoto K, Ogawa R, Fukuda K, et al: Gastric mucosal changes, and sex differences therein, after Helicobacter pylori eradication: A long-term prospective follow-up study. J Gastroenterol Hepatol. 36:2210–2216. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Shah SC, Wang AY, Wallace MB and Hwang JH: AGA clinical practice update on screening and surveillance in individuals at increased risk for gastric cancer in the United States: Expert review. Gastroenterology. 168:405–416.e1. 2025. View Article : Google Scholar : PubMed/NCBI | |
|
Park JY: Population-based Helicobacter pylori screen-and-treat strategies for gastric cancer prevention: Guidance on implementation. IARC Working Group Reports Lyon (FR): International Agency for Research on Cancer; 2025 | |
|
Lee YC, Chiang TH, Chou CK, Tu YK, Liao WC, Wu MS and Graham DY: Association between Helicobacter pylori eradication and gastric cancer incidence: A systematic review and meta-analysis. Gastroenterology. 150:1113–1124.e5. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ford AC, Yuan Y, Park JY, Forman D and Moayyedi P: Eradication therapy to prevent gastric cancer in Helicobacterpylori-positive individuals: Systematic review and meta-analysis of randomized controlled trials and observational studies. Gastroenterology. 169:261–276. 2025. View Article : Google Scholar : PubMed/NCBI | |
|
Choi IJ, Kook MC, Kim YI, Cho SJ, Lee JY, Kim CG, Park B and Nam BH: Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med. 378:1085–1095. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Choi IJ, Kim CG, Lee JY, Kim YI, Kook MC, Park B and Joo J: Family history of gastric cancer and Helicobacter pylori treatment. N Engl J Med. 382:427–436. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, Terao S, Amagai K, Hayashi S and Asaka M; Japan Gast Study Group, : Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: An open-label, randomised controlled trial. Lancet. 372:392–397. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Rokkas T, Rokka A and Portincasa P: A systematic review and meta-analysis of the role of Helicobacter pylori eradication in preventing gastric cancer. Ann Gastroenterol. 30:414–423. 2017.PubMed/NCBI | |
|
Rugge M, Genta RM, Fassan M, Valentini E, Coati I, Guzzinati S, Savarino E, Zorzi M, Farinati F and Malfertheiner P: OLGA gastritis staging for the prediction of gastric cancer risk: A long-term follow-up study of 7436 patients. Am J Gastroenterol. 113:1621–1628. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Capelle LG, de Vries AC, Haringsma J, Ter Borg F, de Vries RA, Bruno MJ, van Dekken H, Meijer J, van Grieken NCT and Kuipers EJ: The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc. 71:1150–1158. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Dixon MF, Genta RM, Yardley JH and Correa P: Classification and grading of gastritis: The updated sydney system. International workshop on the histopathology of gastritis, houston 1994. Am J Surg Pathol. 20:1161–1181. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Pimentel-Nunes P, Libânio D, Marcos-Pinto R, Areia M, Leja M, Esposito G, Garrido M, Kikuste I, Megraud F, Matysiak-Budnik T, et al: Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European society of gastrointestinal endoscopy (ESGE), European Helicobacter and microbiota study group (EHMSG), European society of pathology (ESP), and sociedade portuguesa de endoscopia digestiva (SPED) guideline update 2019. Endoscopy. 51:365–388. 2019.PubMed/NCBI | |
|
Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, Haruma K, Asaka M, Uemura N, Malfertheiner P, et al: Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 64:1353–1367. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
den Hollander WJ, Holster IL, den Hoed CM, Capelle LG, Tang TJ, Anten MP, Prytz-Berset I, Witteman EM, ter Borg F, Hartog G, et al: Surveillance of premalignant gastric lesions: A multicentre prospective cohort study from low incidence regions. Gut. 68:585–593. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Marcos P, Brito-Gonçalves G, Libânio D, Pita I, Castro R, Sá I, Dinis-Ribeiro M and Pimentel-Nunes P: Endoscopic grading of gastric intestinal metaplasia on risk assessment for early gastric neoplasia: Can we replace histology assessment also in the west? Gut. 69:1762–1768. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, et al: Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 404:398–402. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
González CA, Sala N and Capellá G: Genetic susceptibility and gastric cancer risk. Int J Cancer. 100:249–260. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Tsugane S and Sasazuki S: Diet and the risk of gastric cancer: Review of epidemiological evidence. Gastric Cancer. 10:75–83. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Sung JJY, Coker OO, Chu E, Szeto CH, Luk STY, Lau HCH and Yu J: Gastric microbes associated with gastric inflammation, atrophy and intestinal metaplasia 1 year after Helicobacter pylori eradication. Gut. 69:1572–1580. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Song CH, Choi Y, Kim N, Ha S, Park JH, Lee HK, Shin CM and Ahn S: Longitudinal remodeling of gastric microbiota following Helicobacter pylori eradication reveals an eradication-associated microbial signature in gastric cancer. Front Cell Infect Microbiol. 16:18484372026. View Article : Google Scholar : PubMed/NCBI | |
|
Ferreira RM, Pereira-Marques J, Pinto-Ribeiro I, Costa JL, Carneiro F, Machado JC and Figueiredo C: Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota. Gut. 67:226–236. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Coker OO, Dai Z, Nie Y, Zhao G, Cao L, Nakatsu G, Wu WKK, Wong SH, Chen Z, Sung JJY and Yu J: Mucosal microbiome dysbiosis in gastric carcinogenesis. Gut. 67:1024–1032. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Gantuya B, El-Serag HB, Matsumoto T, Ajami NJ, Oyuntsetseg K, Azzaya D, Uchida T and Yamaoka Y: Gastric microbiota in Helicobacter pylori-negative and -positive gastritis among high incidence of gastric cancer area. Cancers (Basel). 11:5042019. View Article : Google Scholar : PubMed/NCBI | |
|
Salama NR, Hartung ML and Müller A: Life in the human stomach: Persistence strategies of the bacterial pathogen Helicobacter pylori. Nat Rev Microbiol. 11:385–399. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Backert S, Tegtmeyer N and Fischer W: Composition, structure and function of the Helicobacter pylori cag pathogenicity island encoded type IV secretion system. Future Microbiol. 10:955–965. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hatakeyama M: Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat Rev Cancer. 4:688–694. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Cover TL and Blaser MJ: Helicobacter pylori in health and disease. Gastroenterology. 136:1863–1873. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Boquet P and Ricci V: Intoxication strategy of Helicobacter pylori VacA toxin. Trends Microbiol. 20:165–174. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Fischer W: Assembly and molecular mode of action of the Helicobacter pylori Cag type IV secretion apparatus. FEBS J. 278:1203–1212. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Murata-Kamiya N, Kurashima Y, Teishikata Y, Yamahashi Y, Saito Y, Higashi H, Aburatani H, Akiyama T, Peek RM Jr, Azuma T and Hatakeyama TM: Helicobacter pylori CagA interacts with E-cadherin and deregulates the beta-catenin signal that promotes intestinal transdifferentiation in gastric epithelial cells. Oncogene. 26:4617–4626. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Bessède E, Dubus P, Mégraud F and Varon C: Helicobacter pylori infection and stem cells at the origin of gastric cancer. Oncogene. 34:2547–2555. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hayakawa Y, Fox JG and Wang TC: The origins of gastric cancer from gastric stem cells: Lessons from mouse models. Cell Mol Gastroenterol Hepatol. 3:331–338. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Houghton J, Stoicov C, Nomura S, Rogers AB, Carlson J, Li H, Cai X, Fox JG, Goldenring JR and Wang TC: Gastric cancer originating from bone marrow-derived cells. Science. 306:1568–1571. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Kusters JG, van Vliet AHM and Kuipers EJ: Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev. 19:449–490. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Peek RM Jr and Blaser MJ: Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer. 2:28–37. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N and Schlemper RJ: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 345:784–789. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Ihan A, Tepez B, Gubina M, Malovrh T and Kopitar A: Diminished interferon-gamma production in gastric mucosa T lymphocytes after H. pylori eradication in duodenal ulcer patients. Hepatogastroenterology. 46:1740–1745. 1999.PubMed/NCBI | |
|
Kim MJ, Je Y, Chun J, Youn YH, Park H, Nahm JH and Kim JH: Helicobacter pylori eradication is associated with a reduced risk of metachronous gastric neoplasia by restoring immune function in the gastric mucosa. Helicobacter. 30:e700302025. View Article : Google Scholar : PubMed/NCBI | |
|
Fu Y, Tong J, Zhu M, Xu L, Huang F, Zhang Y, Wang X, Wang Z, Zhang J, Lv J, et al: Helicobacter pylori-induced inflammatory cancer transformation microenvironment drives gastric carcinogenesis. Cell Mol Gastroenterol Hepatol. 20:1017572026. View Article : Google Scholar : PubMed/NCBI | |
|
Huang KK, Ma H, Chong RHH, Uchihara T, Lian BSX, Zhu F, Sheng T, Srivastava S, Tay ST, Sundar R, et al: Spatiotemporal genomic profiling of intestinal metaplasia reveals clonal dynamics of gastric cancer progression. Cancer Cell. 41:2019–2037.e8. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Kim H, Kim J, Jeong IH, Park E, Yoo M, Yoon S, Lee D, Myung J, Choi E, Goldenring JR and Jang B: Hybrid identity and distinct methylation profiles of incomplete intestinal metaplasia in the stomach. Gut. 75:10–23. 2026. View Article : Google Scholar | |
|
Curtius K, Wright NA and Graham TA: An evolutionary perspective on field cancerization. Nat Rev Cancer. 18:19–32. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Collins GS, Reitsma JB, Altman DG and Moons KGM: Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement. Ann Intern Med. 162:55–63. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M and Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics, : REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 93:387–391. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Hu W, Chen ZM, Wang Y, Yang C, Wu ZY, You LJ, Zhai ZY, Huang ZY, Zhou P, Huang SL, et al: Single-cell RNA sequencing dissects the immunosuppressive signatures in Helicobacter pylori-infected human gastric ecosystem. Nat Commun. 16:39032025. View Article : Google Scholar : PubMed/NCBI | |
|
Huang RJ, Wichmann IA, Su A, Sathe A, Shum MV, Grimes SM, Meka R, Almeda A, Bai X, Shen J, et al: A spatial transcriptomic signature of 26 genes resolved at single-cell resolution characterizes high-risk gastric cancer precursors. NPJ Precis Oncol. 9:522025. View Article : Google Scholar : PubMed/NCBI | |
|
Koch MRA, Gong R, Friedrich V, Engelsberger V, Kretschmer L, Wanisch A, Jarosch S, Ralser A, Lugen B, Quante M, et al: CagA-specific gastric CD8+ tissue-resident T cells control Helicobacter pylori during the early infection phase. Gastroenterology. 164:550–566. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Law AMK, Chen J, Colino-Sanguino Y, Rodriguez de la Fuente L, Fang G, Grimes SM, Lu H, Huang RJ, Boyle ST, Venhuizen J, et al: ALTEN: A high-fidelity primary tissue-engineering platform to assess cellular responses ex vivo. Adv Sci (Weinh). 9:e21033322022. View Article : Google Scholar : PubMed/NCBI | |
|
Wolff RF, Moons KGM, Riley RD, Whiting PF, Westwood M, Collins GS, Reitsma JB, Kleijnen J and Mallett S; PROBAST Group†, : PROBAST: A tool to assess the risk of bias and applicability of prediction model studies. Ann Intern Med. 170:51–58. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Vickers AJ and Elkin EB: Decision curve analysis: A novel method for evaluating prediction models. Med Decis Making. 26:565–574. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Netea MG, Domínguez-Andrés J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E, Joosten LAB, van der Meer JWM, Mhlanga MM, Mulder WJM, et al: Defining trained immunity and its role in health and disease. Nat Rev Immunol. 20:375–388. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Szabo PA, Miron M and Farber DL: Location, location, location: Tissue resident memory T cells in mice and humans. Sci Immunol. 4:eaas96732019. View Article : Google Scholar : PubMed/NCBI | |
|
Sorini C, Tripathi KP, Wu S, Higdon SM, Wang J, Cheng L, Banerjee S, Reinhardt A, Kreslavsky T, Thorell A, et al: Metagenomic and single-cell RNA-Seq survey of the Helicobacter pylori-infected stomach in asymptomatic individuals. JCI Insight. 8:e1610422023. View Article : Google Scholar : PubMed/NCBI | |
|
Li N, Chen S, Xu X, Wang H, Zheng P, Fei X, Ke H, Lei Y, Zhou Y, Yang X, et al: Single-cell transcriptomic profiling uncovers cellular complexity and microenvironment in gastric tumorigenesis associated with Helicobacter pylori. J Adv Res. 74:471–491. 2025. View Article : Google Scholar : PubMed/NCBI | |
|
Nowicki-Osuch K, Zhuang L, Cheung TS, Black E, Masqué-Soler N, Devonshire G, Redmond A, Freeman A, di Pietro M, Pilonis N, et al: Single-cell RNA sequencing unifies developmental programs of esophageal and gastric intestinal metaplasia. Cancer Discov. 13:1346–1363. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Kim J, Park C, Kim KH, Kim EH, Kim H, Woo JK, Seong JK, Nam KT, Lee YC and Cho SY: Single-cell analysis of gastric pre-cancerous and cancer lesions reveals cell lineage diversity and intratumoral heterogeneity. NPJ Precis Oncol. 6:92022. View Article : Google Scholar : PubMed/NCBI | |
|
Chen X, Jiang X, Wang S, Xia J, Wang W, Fu X, Yukun P, Liu Z, Li Y, Zhang M and Ding Y: Integrated single-cell and spatial transcriptomics reveal the differentiation drivers of gastric epithelial lineage progression. Front Immunol. 17:17128302026. View Article : Google Scholar : PubMed/NCBI | |
|
Ye Y, Gong X, Liu S, Hu N, Zhang H, Fei X, Huang A, Fan W, Chen Z, Wang H, et al: A single-cell multi-omics atlas defines the cellular and molecular landscape of gastric intestinal metaplasia. J Transl Med. 24:7242026. View Article : Google Scholar : PubMed/NCBI | |
|
Yin H, Zhang H, Zheng S, Guo R, Wen J, Liu M, Li A, Zhao M, Yuan Y and Gong Y: Dissecting the differentiation origins of intestinal metaplasia and early intestinal-type gastric cancer in gastric antrum by single-cell RNA profiling. NPJ Precis Oncol. 10:1672026. View Article : Google Scholar : PubMed/NCBI | |
|
Tsai CJ, Herrera-Goepfert R, Tibshirani RJ, Yang S, Mohar A, Guarner J and Parsonnet J: Changes of gene expression in gastric preneoplasia following Helicobacter pylori eradication therapy. Cancer Epidemiol Biomarkers Prev. 15:272–280. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Kumar V, Ramnarayanan K, Sundar R, Padmanabhan N, Srivastava S, Koiwa M, Yasuda T, Koh V, Huang KK, Tay ST, et al: Single-cell atlas of lineage states, tumor microenvironment and subtype-specific expression programs in gastric cancer. Cancer Discov. 12:670–691. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang M, Hu S, Min M, Ni Y, Lu Z, Sun X, Wu J, Liu B, Ying X and Liu Y: Dissecting transcriptional heterogeneity in primary gastric adenocarcinoma by single cell RNA sequencing. Gut. 70:464–475. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, Gordon S, Hamilton JA, Ivashkiv LB, Lawrence T, et al: Macrophage activation and polarization: Nomenclature and experimental guidelines. Immunity. 41:14–20. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Su Z, He Y, You L, Chen J, Zhang G and Liu Z: SPP1+ macrophages and FAP+ fibroblasts promote the progression of pMMR gastric cancer. Sci Rep. 14:262212024. View Article : Google Scholar : PubMed/NCBI | |
|
Qiu L, Zhao X, Yao S, Fei Y, Gong Y, Zhou Z, Jiao S and Xu J: Multi-omics analyses reveal interactions between GREM1+ fibroblasts and SPP1+ macrophages in gastric cancer. NPJ Precis Oncol. 9:1642025. View Article : Google Scholar : PubMed/NCBI | |
|
Ma G, Liu X, Jiang Q, Li S, Wu Q, Liang B, Sun F, Gu C, Liao W, Zhang Z, et al: Identification of a stromal immunosuppressive barrier orchestrated by SPP1+/C1QC+ macrophages and CD8+ exhausted T cells driving gastric cancer immunotherapy resistance. Front Immunol. 16:16185912025. View Article : Google Scholar : PubMed/NCBI | |
|
Lundgren A, Suri-Payer E, Enarsson K, Svennerholm AM and Lundin BS: Helicobacter pylori-specific CD4+ CD25high regulatory T cells suppress memory T-cell responses to H. pylori in infected individuals. Infect Immun. 71:1755–1762. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Amedei A, Cappon A, Codolo G, Cabrelle A, Polenghi A, Benagiano M, Tasca E, Azzurri A, D'Elios MM, DelPrete G and de Bernard M: The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses. J Clin Invest. 116:1092–1101. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Rad R, Brenner L, Bauer S, Schwendy S, Layland L, da Costa CP, Reindl W, Dossumbekova A, Friedrich M, Saur D, et al: CD25+/Foxp3+ T cells regulate gastric inflammation and Helicobacter pylori colonization in vivo. Gastroenterology. 131:525–537. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Kao JY, Zhang M, Miller MJ, Mills JC, Wang B, Liu M, Eaton KA, Zou W, Berndt BE, Cole TS, et al: Helicobacter pylori immune escape is mediated by dendritic cell-induced Treg skewing and Th17 suppression in mice. Gastroenterology. 138:1046–1054. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Oertli M, Noben M, Engler DB, Semper RP, Reuter S, Maxeiner J, Gerhard M, Taube C and Müller A: Helicobacter pylori γ-glutamyl transpeptidase and vacuolating cytotoxin promote gastric persistence and immune tolerance. Proc Natl Acad Sci USA. 110:3047–3052. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Hitzler I, Sayi A, Kohler E, Engler DB, Koch KN, Hardt WD and Müller A: Caspase-1 has both proinflammatory and regulatory properties in Helicobacter infections, which are differentially mediated by its substrates IL-1β and IL-18. J Immunol. 188:3594–3602. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Caruso R, Pallone F and Monteleone G: Emerging role of IL-23/IL-17 axis in H pylori-associated pathology. World J Gastroenterol. 13:5547–5551. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Xia T, Zhang Z, Xie J, Yuan H, Ren Y, Xu Y, Ning J, Li B and Wu C: Gastric mucosal CD8+TRM cells are recruited through CXCR5-CXCL13 axis in Helicobacter pylori infected subjects. Cytokine. 190:1569042025. View Article : Google Scholar : PubMed/NCBI | |
|
Gong R, Huang B, Ralser A, Friedrich V, Mibus C, Engelsberger V, Koch MRA, Skerhut M, Giese T, Andrä I, et al: CagA-dependent Hobit+ gastric tissue-resident memory T cells confer full protection from Helicobacter pylori reinfection. Gut. 74:1792–1803. 2025. View Article : Google Scholar : PubMed/NCBI | |
|
Bockerstett KA, Lewis SA, Noto CN, Ford EL, Saenz JB, Jackson NM, Ahn TH, Mills JC and DiPaolo RJ: Single- cell transcriptional analyses identify lineage-specific epithelial responses to inflammation and metaplastic development in the gastric corpus. Gastroenterology. 159:2116–2129.e4. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Petersen CP, Mills JC and Goldenring JR: Murine models of gastric corpus preneoplasia. Cell Mol Gastroenterol Hepatol. 3:11–26. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Nam KT, Lee HJ, Sousa JF, Weis VG, O'Neal RL, Finke PE, Romero-Gallo J, Shi G, Mills JC, Peek RM Jr, et al: Mature chief cells are cryptic progenitors for metaplasia in the stomach. Gastroenterology. 139:2028–2037.e9. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Goldenring JR and Nam KT: Oxyntic atrophy, metaplasia, and gastric cancer. Prog Mol Biol Transl Sci. 96:117–131. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Mills JC and Goldenring JR: Metaplasia in the stomach arises from gastric chief cells. Cell Mol Gastroenterol Hepatol. 4:85–88. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Coussens LM and Werb Z: Inflammation and cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Mantovani A, Allavena P, Sica A and Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Cancer Genome Atlas Research Network, . Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 513:202–209. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, Liu J, Yue YG, Wang J, Yu K, et al: Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 21:449–456. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Banks M, Graham D, Jansen M, Gotoda T, Coda S, di Pietro M, Uedo N, Bhandari P, Pritchard DM, Kuipers EJ, et al: British society of gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. Gut. 68:1545–1575. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Sung JK: Diagnosis and management of gastric dysplasia. Korean J Intern Med. 31:201–209. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Song L and Yu QY: Stratified management of residual gastric cancer risk after Helicobacter pylori eradication. Front Microbiol. 17:17794902026. View Article : Google Scholar : PubMed/NCBI | |
|
Ding T, Hu W, Qi X, Zhang Y and Wang H: Advances in Helicobacter pylori-mediated oncogenic signaling pathways in gastric cancer: From pathological evolution to clinical application prospects (Review). Oncol Lett. 32:4082026. View Article : Google Scholar : PubMed/NCBI | |
|
Guan Z, Han L, Chen B, Ma Y, Ni Q, Wang Z, Yang J and Liu Z: Tumor microenvironment in gastric cancer immune tolerance and its therapeutic relevance in immunomodulation (Review). Oncol Lett. 31:1082026. View Article : Google Scholar : PubMed/NCBI | |
|
Moncada R, Barkley D, Wagner F, Chiodin M, Devlin JC, Baron M, Hajdu CH, Simeone DM and Yanai I: Integrating microarray-based spatial transcriptomics and single-cell RNA-seq reveals tissue architecture in pancreatic ductal adenocarcinomas. Nat Biotechnol. 38:333–342. 2020. View Article : Google Scholar : PubMed/NCBI |